Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...